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Genetic and epigenetic analyses of MBD3 in colon and lung cancer
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MBD3 is a member of the methyl-CpG-binding domain family and is located on chromosome 19p13.3, a region of loss of
heterozygosity in colon and lung cancers. We therefore screened samples for abnormalities in MBD3. Our results indicate that MBD3
is not a major target of genetic and epigenetic alteration in these cancers.
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In humans, the somatic genome is globally methylated, with the
exception of CpG islands. CpG islands are CG-rich regions of DNA,
which are coincident with the promoters of 60% of human
housekeeping genes (Antequera and Bird, 1994). DNA methylation
is an important epigenetic modification in the human genome,
playing an essential role in the control of gene expression. It is well
established that DNA methylation is extensively involved in gene
imprinting, X inactivation and development. Aberrant methylation
of CpG islands in the promoter of many cancer-related genes
results in silencing of their expression compared with normal cells
of the same tissue (Tycko, 2000).
The signal encoded by a particular pattern of DNA methylation
is transduced through proteins that bind to methylated CpGs.
These proteins contain a specific domain, the methyl-CpG-binding
domain (MBD) (Nan et al, 1993). So far, five human MBD proteins
have been identified as members of this protein family: MBD1,
MBD2, MBD3, MBD4 and MECP2. MBD3 shares about 70% of
overall identity with MBD2 over most of their length (Hendrich
and Bird, 1998). MBD3 is a subunit of the NuRD complex that has
nucleosome remodelling and histone deacetylase activities (Wade
et al, 1998, 1999; Zhang et al, 1999). Although MBD3 does not itself
bind directly to methylated DNA, several lines of evidence suggest
that MBD3 does play a role as part of the NuRD complex in the
maintenance of transcriptionally repressed chromatin. MBD3 is
crucial to normal mammalian development as knockout of Mbd3
in mice is embryonic lethal (Hendrich et al, 2001). Mutations or
abnormal expression of MBD3 could therefore play a role in
tumorigenesis via inappropriate regulation of other gene expres-
sion. Other members (MBD2 and MBD4) of the MBD family have
already been associated with colorectal cancer, albeit in different
mechanisms. Maintenance of MBD2 expression (normal function
being the suppression of transcription from methylated DNA) is
required for tumour formation in APCmin mice (Sansom et al,
2003). Mutation of MBD4 (normal function being the repair of
methyl-CpG deamination events) occurs in microsatellite unstable
tumours (Bader et al, 1999) and absence of the gene in MBD4 null
mice leads to increased genomic mutations and tumour burden in
APCmin mice (Millar et al, 2002).
MBD3 is located on chromosome 19p13.3, a region reported to
suffer 20–50% loss of heterozygosity (LOH) in sporadic colorectal
carcinomas (Dong et al, 1998; Resta et al, 1998; Trojan et al, 2000).
According to the data compiled by the Human Genome Mapping
Project (available on the website http://www.ncbi.nlm.nih.gov/),
MBD3 is within about 500 kb of the gene LKB1/STK11, which is
mutated or abnormally methylated in Peutz–Jeghers syndrome.
Peutz–Jeghers patients have hamartomatous polyposis of the
gastrointestinal tract and an increased risk of a range of cancers
including colon. LKB1 is rarely mutated or methylated (maximum
about 20%), however, in sporadic colorectal carcinomas (Avizie-
nyte et al, 1998; Resta et al, 1998; Esteller et al, 2000; Launonen
et al, 2000; Trojan et al, 2000), raising the possibility that another
gene in the vicinity is involved in these cancers. The short arm of
chromosome 19 is also implicated in up to 86% of lung cancers
(Lukeis et al, 1990; Virmani et al, 1998; Sanchez-Cespedes et al,
2001). In the light of the location of MBD3 in a region of
chromosomal loss and its known functions in transcription
suppression, it is considered as a candidate tumour-suppressor
gene. We therefore performed a mutation screen, expression study
and methylation status assay to investigate the possible role of
MBD3 in the aetiology of colon and lung cancers.
MATERIAL AND METHODS
Samples, DNA and RNA extractions
Cancer cell lines were obtained from the European Collection of
Cell Cultures (ECACC)/ATCC, comprising seven colon cancers, 20
lung cancers and one normal lung cell (BW1799) (see Table 1). In
all, 51 primary colon tumour samples were part of an unselected,
anonymised collection from patients at the Royal Infirmary
Edinburgh. DNAs were extracted by standard methods from
pellets of cell lines, or from frozen primary tumours. Total RNAs of
cell lines were extracted by using Trizol Reagent (Invitrogen)
according to the manufacturer’s protocol; normal colon tissue
RNA was from Stratagene. PolyAþ RNA was isolated using a
Qiagen direct mRNA kit according to the manufacturer’s protocol.
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A measure of 10mg of polyAþ RNA was electrophoresed on a 7%
formaldehyde gel and then transferred to Hybond-N (Amersham)
nylon membrane by capillary transfer. The membrane was
crosslinked by UV light before hybridisation. The northern blot
was pre-hybridised for 30 min at 681C with ExpressHyb solution
(Clontech) and hybridised for 1 h at 681C in the same solution with
50 mCi 32P-labelled MBD3 cDNA probe. The cDNA probe was PCR
amplified by primer pair MBD3/3, 50-ACATGCTGGGGGACGTG-
GA, and MBD3/30, 50-GCTGCACAGTGGGTGATGTGA, which
generated a 587 bp fragment. After appropriate washings, the
membrane was exposed to Kodak XAR5 film at 701C for up to 3
days. Autoradiographic exposure of a low specific activity (so as
not to obscure the nearby 2.4 kb MBD3 band) b-actin probe was
used as a loading control for the lanes.
Examination of MBD3 expression by RT–PCR and
Northern blot hybridisation analyses
Total RNA (10 mg) was reverse transcribed with random hexamers
using the M-MLV Reverse Transcriptase kit (Invitrogen) according
to the manufacturer’s instructions. The cDNA (0.5 ml) was then
amplified in a 20 ml reaction under standard conditions. The PCR
cycle parameters were as follows: an initial denaturing step at 951C
for 5 min, followed by 35 cycles of (30 s at 951C, 30 s at 521C, 30 s at
721C), then 3 min at 721C. The primers used were MBD3/1,
50-GAAGAAGTTCCGCAGCAA, and MBD3/2a, 50-GGTCGCTCTT-
GACCTTGT, which generated a fragment of 260 bp. The PCR
products were run on 1% agarose gel in 1 TAE, and visualised
by ethidium bromide staining.
CpG island methylation status analysis
To examine the methylation status of the MBD3 CpG island,
methylation-sensitive/resistant enzymes (HpaII/MspI) were used to
digest DNA at CCGG sites, followed by PCR amplification. The
presence of the PCR product from HpaII digest indicates that the
DNA is protected by methylation from being cut, while no PCR
product results if the DNA is not methylated. No PCR product will
be obtained from MspI digested DNA because it cuts irrespective
of its methylation status. Genomic DNA (0.5 mg) from cancer cell
lines was digested with 50 U of either HpaII or MspI (NEB) for 16 h
at 371C. The same amounts of fully methylated DNA (Sigma) were
also digested as positive controls. The digest reactions were
phenol : chloroform extracted and ethanol precipitated. Digested
DNAs were then amplified by PCR using primer pairs MBD3/17,
50-ACTGGCAGCTCGCAAGGCACA, and MBD3/18, 50-CGCTGGG-
AGGAGCCCGTTGAG, which cover 531 bp within the CpG islands
in exon 1(see Figure 1). We used Platinum Pfx DNA polymerase
(Invitrogen) to amplify the CG-rich region. Each 50 ml reaction
contained 1 Pfx buffer, 0.3 M dNTP, 1 mM MgSO2, 0.3mM
primers, 5 PCR enhancer solution and 2.5 U Pfx DNA
polymerase. The PCR conditions were 5 min at 971C as a hot
start, then 5 min at 951C followed by 35 cycles of (30 s at 951C, 30 s
at 551C, 2 min at 681C) and finally 5 min at 681C. The PCR
products were run on 1% agarose gels and visualised by ethidium
bromide staining.
Mutational analysis by SSCP and sequencing
PCR of genomic DNA was carried out using six pairs of intron
primers as listed in Table 1. These primer sets covered the entire
Exons
Primer pairs
Primer pairs
Untranslated region
Untranslated region
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Figure 1 (A) MBD3 gene structure. (B) MBD3 CpG island HpaII/MspI
restriction sites (CCGG), from Genbank AC005943.
Table 1 Cell lines and primers used
Cell lines tissue Description Name
Colon Microsatellite stable HT29, SW480, COLO320
Microsatellite unstable HCT116, DLD1/HCT15, LOVO,LS180
Lung Small cell (SCLC) NCI-H69, -H524, -H740, -H1672, -H1092
-H1184, -H1838, COR-L24, -L47, -L51, -L88, -L279,-L311
Non samll cell (NSCLC) NCI-H358, -H835, -H920, -H1648, -H2122, COR-L23, -L105
Primers exon Primer name and sequence PCR conditions per pair
1 17: ACTGGCAGCTCGCAAGGCACA 95 30 , (95 3000 , 55 3000 , 68 20) 35
15: GCACGCACGCACGACGCA 68 30 , Pfx pdymerase+5x Enhancer
2 5: TGGGTTTGGGGTCTTGGGGT 94 30 (94 300 , 55 3000) 35, 72 30
6: GTCACCTGCGTGACGCCA Taq polymerase+10% DMSO
3 7: CAGGCCGGACTGCATATC 94 30 , (94 3000 , 55 3000) 35, 72 30
8: TTGGGGTCGCTGTGCGTT Taq polymerase
4 9: GGGCCACTCTTGAGGTTCACA 94 30 , (94 3000 , 58 3000) 35, 72 30
10: TCCGCCTCCCCTCAGGGA Taq polymerase
5 11: CTTGCGGCTGTTTGTCCA 94 30 , (94 3000 , 58 3000) 35, 72 30
12: TGGAGCAGCAGGGGACCA Taq polymerase+5% DMSO
6 13: TGGTGTTAACGCAAGGTCCA 94 30 , (94 3000 , 58 3000) 35, 72 30
4: CACTGCCAGGACCCGACT Taq polymerase+5% DMSO
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coding region (exons 1–6) of MBD3 and included splice acceptor
and donor sites (see Figure 1). PCR conditions are included in
Table 1. In all, 1 mCi of 33P-dATP (ICN) was added in each 10 ml
reaction. PCR products were denatured and run on 0.5 SequaGel
MD gels (National Diagnostics) containing 10% glycerol and 0.6
TBE for 18 h at 6W at room temperature. To identify base changes,
the PCR products showing aberrantly migrated bands on SSCP gels
were sequenced in both strands using the Thermo Sequenase
Radiolabelled Terminator Cycle Sequencing Kit (USB) according
to the manufacturer’s protocol.
RESULTS
We found three aberrant SSCP bandshifts in 28 cell lines and 51
primary tumour samples, which were then sequenced (Figure 2A,
B). All of the changes were heterozygous, as seen by the retention
of normal bands in SSCP or sequencing gels, and all were in cell
lines. Specifically, in exon 3 of DLD1/HCT15 (cell lines derived
from the same tumour), a G to A transition in codon 104 coded for
a silent change (T104). In exon 6 of DLD1/HCT15, a C to A
transversion caused a leucine-to-methionine substitution at
residue 248 (L248M). In exon 5 of H69, a C to A transition was
detected encoding a leucine to methionine substitution at residue
161 (L161M). No changes were found in the primary colon
tumours. Since matching normal tissues do not exist for the cell
lines to confirm somatic mutation events in these cases, we then
screened independent normal DNAs to see if these differences exist
in cells of noncancerous individuals. The exon 5 variant was found
in one out of 47 normals, indicating that it is probably a rare
polymorphism, but the exon 6 substitution was not seen in 54
normals, nor the silent exon 3 variant in 47 normals. There is thus
a possibility that the L248M change is a true cancer-related
mutation, although it is a conservative substitution and so may
have little functional effect.
RT– PCR showed that MBD3 expression is detectable in all the
cell lines tested (data not shown), an observation confirmed for a
selection of the colon cancer cell lines by Northern blot
hybridisation of polyAþ RNA (Figure 2C), although expression
in SW480 relative to b-actin appears lower than for other cell lines.
We went on to test for methylation of the CpG island, but did not
find evidence for methylation in any of the colon (including
SW480) or lung cell lines (see Figure 2D for colon cancer cell lines,
lung cancer cell lines data not shown). The method used to screen
for methylation concentrated on the nine HpaII/MspI sites, all of
which must be methylated to allow PCR and give a positive result
after HpaII digestion, and therefore gives a qualitative (total vs
partial/no methylation) rather than quantitative assessment of
methylation.
DISCUSSION
Inactivating LKB1/STK11 germline mutations in combination with
loss of the wild-type allele by chromosomal loss or methylation are
responsible for the development of hamartomatous polyps and
adenocarcinomas in Peutz–Jeghers syndrome patients. LKB1/
STK11, however, is rarely involved in sporadic colon cancer cases
and at most 33% of NSCLC cases (Sanchez-Cespedes et al, 2002),
leading us to consider the role of MBD3 as an alternative tumour-
suppressor gene on this location. This gene is tightly linked to
LKB1/STK11, being only 500 kb away on chromosome 19p13.3. To
investigate the role of MBD3 in colon and lung tumorigenesis, we
assayed for mutations, lack of expression and promoter methyla-
tion. We found two missense changes, one out of seven colon
cancer cell lines and one out of 20 lung cancer cell lines, and none
in colon primaries. Both changes were located outside the MBD,
and one appears to be a naturally occurring rare polymorphism.
The coincidence of the missense and silent mutations in DLD1/
HCT15 may simply reflect the mismatch repair defect of these cell
lines due to MSH6 mutation. RT–PCR amplification and Northern
blot hybridisation of the cell lines showed clear expression of the
gene, while methylation-sensitive restriction enzyme/PCR analyses
showed that none were fully methylated across the region tested.
Hypermethylation of other genes involved in tumorigenesis
usually shows methylation across the bulk of the associated CpG
island. We would therefore have expected the nine CpG sites we
tested of the MBD3 CpG island (about 50% of the putative CpG
island for MBD3) to have been methylated in a significant
proportion of cells to give a detectable PCR result if this
phenomenon had occurred. Our expression and methylation
results are consistent with a lack of significant aberrant, tumour-
associated silencing of the gene. In summary, we conclude that
MBD3 is not a major target of genetic or epigenetic alteration in
colon and lung cancer.
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